Clinical Trial Results: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2b/Phase 3 clinical trial results for linsitinib in active moderate to severe thyroid eye disease (Graves orbitopathy).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Orbitopathy
• Thyroid Eye Disease

Drugs mentioned

• Linsitinib (linsitinib)

Snippet

Sponsor: Sling Therapeutics, Inc. | Conditions: Thyroid Eye Disease, Graves Orbitopathy | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2026-08-26